Although some literature suggests that the potential contribution of bone marrow-derived cells, such as fibrocytes and MSCs, to fibrogenic myofibroblasts has not been excluded (98, 99), some clinical trials using autologous and allogeneic MSCs transplantation have been carried out in patients with fibrosis, with a slight improvement of clinical parameters (such as albumin, creatinine) without serious adverse reactions, which indicates that MSCs have potential therapeutic effects on liver diseases (50, 100). Here, ALB is linked to liver disorder.